Form 4: Sage Therapeutics Executive Gregory Shiferman Reports Stock Transaction

Sentiment:

SEC Form 4 Filing


Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Summary

  • On March 26, 2025, Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics, Inc., filed a Form 4.
  • The report details a transaction on March 24, 2025, where 79 shares of common stock were disposed of to cover tax obligations.
  • This was due to the vesting of 235 restricted stock units (RSUs) granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan.
  • Following the transaction, Shiferman beneficially owns 30,680 shares of Sage Therapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a standard regulatory filing related to stock transactions for tax purposes.

Industry Context

This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it is a routine tax-related stock disposal.

Key Dates

DateDescription
2014Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan
November 1, 2024Date of Power of Attorney
October 28, 2021Date of RSU grant
September 24, 2022Initial 25% vesting of RSU grant
March 24, 2025Date of stock transaction (disposal of shares for tax withholding)
March 26, 2025Date of Form 4 filing

Keywords

Form 4, Sage Therapeutics, Stock Transaction, Gregory Shiferman, RSU Vesting, Tax Withholding, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.